Breast Cancer, Healthy Volunteers
Conditions
Brief summary
Primary Objectives: * To assess the excretion balance after oral and IV administration of \[14C\]-SAR439859 * To assess PK of total radioactivity, \[14C\] -SAR439859 and its metabolite (M7) after IV administration of \[14C\]-SAR439859 and, PK of radioactivity, SAR439859 and M7 after oral administration of SAR439859 alone or with \[14C\]-SAR439859 * To assess IV clearance and absolute bioavailability of SAR439859 using microdose of \[14C\]-SAR439859 tracer on top of a single tablet oral dose. * To assess relative bioavailability of SAR439859 given as tablet or solution Secondary objectives: * To collect samples in order to assess metabolic profile in plasma and excreta of SAR439859 after oral administration of \[14C\]-SAR439859 as solution, contribution in plasma of SAR439859 and metabolite relative to total radioactivity and identify metabolites (samples will be analyzed according to metabolic analysis plan and results will be documented in a separate report). * To assess safety and tolerance of SAR439859
Detailed description
Total study duration is 3 to 10 weeks, including a screening period of up to 27 days, treatment period of up to 16 days and a follow-up and end of study of up to 4 weeks.
Interventions
DRUGamcenestrant
Tablet Oral
DRUG[14C]-SAR439859 microtracer
Solution for infusion Intravenous
DRUG[14C]-SAR439859
Powder for oral solution Oral
Sponsors
Sanofi
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
Female participants (age between 40 and 75 years old) who are postmenopausal or had post-bilateral surgical oophorectomy not linked to a history of cancer. Participants who are overtly healthy. Body weight within 40.0 and 95.0 kg and body mass index (BMI) within the range 18.0 and 30 kg/m2 (inclusive). Capable of giving signed informed consent.
Exclusion criteria
Subject has clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening. Subject who had severe course of COVID-19 (i.e., hospitalization, extracorporeal membrane oxygenation, mechanically ventilated). Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month). Blood donation, any volume (usually approximately 500 mL), within 2 months before inclusion. Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day). Smoking regularly more than 5 cigarettes or equivalent per week, unable to stop smoking during the study (occasional smoker can be enrolled). Excessive consumption of beverages containing xanthine bases (more than 5 cups or glasses per day). Subjects who are occupationally exposed to radiation as defined in the Ionizing Radiation Regulations 2017. Participation in a trial with \[13C\] or \[14C\] radiolabeled medication in the 12 months preceding the study. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relative bioavailability of SAR439859 after oral administration | Day 1 to Day 5, Day 7 to Day 11 | — |
| Percentage of radioactive dose, SAR439859 and M7 excreted in urine and feces after IV administration | Day 1 to Day 6 | — |
| Percentage of radioactive dose excreted in urine and feces after oral administration | Day 7 up to max Day 44 | — |
| Assessment of Pharmacokinetic (PK) parameter: AUC for radioactivity and SAR439859 after IV administration | Day 1 to Day 3 | Area under the plasma concentration versus time curve extrapolated to infinity |
| Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after IV administration | Day 1 to Day 3 | Terminal half-life associated with the terminal slope (λz) |
| Assessment of PK parameter: CL for SAR439859 after IV administration | Day 1 to Day 3 | Total body clearance |
| Assessment of PK parameter: AUC ratios after IV administration | Day 1 to Day 3 | SAR439859 to radioactivity ratio for plasma AUC |
| Assessment of PK parameter: Cmax for radioactivity and SAR439859 after oral administration | Day 1 to Day 5, Day 7 to Day 11 | Maximum plasm concentration observed |
| Assessment of PK parameter: tmax for radioactivity and SAR439859 after oral administration | Day 1 to Day 5, Day 7 to Day 11 | Time to reach Cmax |
| Assessment of PK parameter: AUC for radioactivity and SAR439859 after oral administration | Day 1 to Day 5, Day 7 to Day 11 | — |
| Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after oral administration | Day 1 to Day 5, Day 7 to Day 11 | — |
| Assessment of PK parameter: AUC ratios after oral administration | Day 7 to Day 11 | SAR439859 to radioactivity ratio for plasma AUC |
| Assessment of PK parameter: Cmax for M7 after IV and oral administration | Day 1 to Day 5, Day 7 to Day 11 | — |
| Assessment of PK parameter: AUC for M7 after IV and oral administration | Day 1 to Day 5, Day 7 to Day 11 | — |
| Assessment of PK parameter: t1/2z for M7 after IV and oral administration | Day 1 to Day 5, Day 7 to Day 11 | — |
| Assessment of PK parameter: Rmet Cmax after IV and oral administration | Day 1 to Day 5, Day 7 to Day 11 | M7 to SAR439859 ratio for plasma Cmax |
| Assessment of PK parameter: Rmet AUC after IV and oral administration | Day 1 to Day 5, Day 7 to Day 11 | M7 to SAR439859 ratio for plasma AUC |
| Absolute oral bioavailability of SAR439859 | Day 1 to Day 5, Day 7 to Day 11 | Absolute oral bioavailability, expressed as a percentage, estimated from AUCs obtained after oral and IV administration |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events | Day 1 to Day 44 |
Countries
United Kingdom
Outcome results
None listed